Brad Haverkos
Associate Professor · University of Colorado School of Medicine
Credentials: · · · · · · ·
History
2013–2015Wright State University
- 2001–2005
Miami University of Ohio
Research
Blood · 2017 · First of 26 authors · 206 citations
Review · Current Hematologic Malignancy Reports · 2016 · First of 11 authors · Corresponding · 169 citations
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2022 · 169 citations
18 papers
17 papers
10 papers
10 papers
9 papers
8 papers
7 papers · 3 as a resident
7 papers
Clinical trials
- 2023–2027
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Principal investigator · Recruiting · Phase 1
SciTech Development, Inc.
- 2021–2022
POLA+BR for Relapsed or Refractory DLBCL
Principal investigator · Withdrawn · Phase 2
University of Colorado, Denver
- 2018–2022
Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas
Principal investigator · Completed · Phase 1, Phase 2
University of Colorado, Denver
- 2024–2028